Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 4, 2015, Pages 158-167

  Feniman Stefano, Greicy Mara Mengue ^a   Zanati Basan, Silméia Garcia ^a   Stefano, Laercio Martins ^a   Xavier, Patrícia Santi ^a   Caramori, Jacqueline Costa Teixeira ^a   Barretti, Pasqual ^a   Jorge Silva Franco, Roberto ^a   Martin, Luis Cuadrado ^a   Castro, Ana Dóris ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

chronic kidney disease; hemodialysis; left ventricular hypertrophy; safety; spironolactone

Indexed keywords

PLACEBO; POTASSIUM; SPIRONOLACTONE; ALDOSTERONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; AGED; BLOOD PRESSURE; DRUG EFFECTS; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ALDOSTERONE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENAL DIALYSIS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84940869815     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944715591448     Document Type: Article

References (36)

1. Acelajado M. Pimenta E. Calhoun D. (2010) Salt and aldosterone: a concert of bad effects. Hypertension 56: 804–805.
2. Agência Nacional de Vigilância Sanitária (2004) Resolução RDC no. 154, de 15 de junho de 2004. Estabelece o Regulamento Técnico para o funcionamento dos Serviços de Diálise. DOU Brasília, 17 de junho de 2004.
3. Agência Nacional de Vigilância Sanitária (2009) Lista de Medicamentos Genéricos. DOU Brasília, 27.03.2009.
4. Bagrov A. Shapiro J. (2008) Endogenous digitalis: pathophysiologic roles and therapeutic applications. Nat Clin Pract Nephrol 4: 378–392.
5. Becker G. Hewitson T. Chrysostomou A. (2009) Aldosterone in clinical nephrology – old hormone, new questions. Nephrol Dial Transplant 24: 2316–2321.
6. Benet L. Kroetz D. Sheiner L. (1995) Pharmacokinetics. In: Ed. Hardman J. Goodman L. Gilman A. Limbird L. (eds), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, pp. 3–20.
7. Blaustein M. Zhang J. Chen L. Song H. Raina H. Kinsey S. et al (2009) The pump, the exchanger, and endogenous ouabain – signaling mechanisms that link salt retention to hypertension. Hypertension 53: 291–298.
8. Congresso Nacional (1999) Lei 9.787 de 1999. Altera a Lei nº 6.360, de 23 de setembro de 1976. Dispõe sobre a vigilância sanitária, estabelece o medicamento genérico, dispõe sobre a utilização de nomes genéricos em produtos farmacêuticos e dá outras providências. DOU Brasília, 11 de fevereiro de 1999.
9. Conselho Nacional de Saúde (1996) Resolução nº 196, de 10 de outubro de 1996. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. DOU Brasília, 16 de outubro de 1996.
10. Chua D. Lo A. Lo C. (2010) Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clinic Cardiol 33: 604–608.
11. Cohn S. Vaswani A. Yasumura S. Yuen K. Ellis K. (1985) Assessment of cellular mass and lean body mass by noninvasive nuclear techniques. J Lab Clin Med 105: 305–311.
12. Daugirdas J. (1995) Simplified equations for monitoring Kt/V, PCRn, eKt/V, and ePCRn. Adv Ren Repalce Ther 2: 295–304.
13. Edwards N. Ferro C. Kirkwood H. Chue C. Young A. Stewart P. et al (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54: 505–512.
14. Essick E. Sam F. (2011) Cardiac Hypertrophy and Fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor. Intern J Hypertens 2011: 1–12.
15. Fedorova O. Shapiro J. Bagrov A. (2010) Endogenous cardiotonic steroids and salt-sensitive hypertension. Biochim Biophys Acta 1802: 1230–1236.
16. Ferreira A. (2010) Excipientes e adjuvantes farmacotécnicos. In: Ed. Ferreira A. (ed), Guia Prático da Farmácia Magistral, Juiz de Fora, Brazil: Pharmabooks, pp.25–130.
17. Finotti P. Palatini P. (1981) Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine thiphosphatase. J Pharmacol Exp Ther 217: 784–790.
18. Foley R. Parfrey P. Harnett J. Kent G. Martin C. Murray D. et al (1995) Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186–192.
19. Fukuda A. Shouichi F. Shuji I. Hiroshi K. Kazuo K. (2010) Effects of mineralocorticoid and angiotensin II receptor blockers on proteinuria and glomerular podocyte protein expression in a model of minimal change nephrotic syndrome. Nephrology 15: 321–326.
20. Hamlyn J. Hamilton B. Manunta P. (1996) Endogenous ouabain, sodium balance and blood pressure: a review and a hypothesis. J Hypertens 14: 151–167.
21. Hammer F. Krane V. Störk S. Röser C. Hofmann K. Pollak N. et al (2014) Rationale and design of the mineralocorticoid receptor antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant 29:1–7.
22. Kushner R. Schoeller D. (1986) Estimation of total body water by bioelectrical impedance analysis. Am J Clin Nutr 44: 417–424.
23. Lang R. Bierig M. Devereux R. Flachskampf F. Foster E. Pellikka P. et al (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiographym a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18: 1440–1463.
24. Lee Y. Chiu H. Su H. Voon W. Lin T. Lai W. et al (2008) Presence of chronic kidney disease and subsequent changes of left ventricular geometry over 4 years in an apparently healthy population aged 60 and older. Hypertens Res 31(Suppl. 5): 913–920.
25. Macedo J. Oliveira I. (2010) Corticosteroides. In: Ed. Silva P. (ed.), Farmacologia. Rio de Janeiro: Guanabara Koogan, pp.822–837.
26. Martin L. Barretti P. Cornejo I. Felipe M. Forti A. Matsubara B. et al (2003) Influence of fluid volume variations on the calculated value of the left ventricular mass measured by echocardiogram in patients submitted to hemodialysis. Ren Fail 25: 43–53.
27. Martin L. Franco R. Gavras I. Matsubara B. Garcia S. Caramori J. et al (2004) Association between hypervolemia and ventricular hypertrophy in hemodialysis patients. Am J Hypertens 17: 1163–1169.
28. Matsumoto Y. Mori Y. Kageyama S. Arihara K. Sugiyama H. Ohumura H. et al (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63: 529–536.
29. Ministério da Saúde (2010) Farmacopeia Brasileira, 5th edn. Brasília: Anvisa.
30. Schoner W. Scheiner-Bobis G. (2008) Role of endogenous cardiotonic steroids in sodium homeostasis. Nephrol Dial Transplant 23: 2723–2729.
31. Schrier R. (2010) Aldosterone ‘escape’ vs ‘breakthrough’. Nat Rev Nephrol 6: 61.
32. Sica D. (2007) The risks and benefits of therapy with aldosterone receptor antagonist therapy. Curr Drug Safet 2: 71–77.
33. Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Hipertensão and Sociedade Brasileira de Nefrologia (2007) V. Diretrizes Brasileiras de Hipertensão Arterial. Arq Bras Cardiol 89: 24–79.
34. Taylor B. Zaleski A. Capizzi J. Ballard K. Troyanos C. Baggish A. et al (2014) Influence of chronic exercise on carotid atherosclerosis in marathon runners. Br Med J Open 4: 1–6.
35. Zoccali C. Benedetto F.A. Mallamaci F. Tripepi G. Giacone G. Cataliotti A. et al. (2001) Prognosis impact of the indexation of left-ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12: 2768–2774.
36. Zolty R. Hynes P. Vittorio T. (2008) Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cadiomyopaty and cardiorenal syndrome. Am J Transplant 8: 2219–2224.